Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tariff System (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Staloral 300, Allergen extract mixture, solution for sublingual use in the treatment of children aged 5-11 years with moderate to severe allergic rhinitis caused by house dust.
- Abecma (idecabtagene vicleucel) in the treatment of patients with plasma cell myeloma
- Breyanzi (lisocabtagene maraleucel) in the treatment of patients with B-cell lymphomas
- Elmiron (pentosan polysulfate sodium) in the treatment of interstitial cystitis with glomerular involvement or Hunner’s lesions
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
